WS
AXSM icon

Wedbush Securities’s Axsome Therapeutics AXSM Stock Holding History

Wedbush Securities’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,818
Closed -$388K – 1108
2024
Q2 		$388K Sell
4,818
-3,479
-42% -$258K 0.01% 731
2024
Q1 		$662K Sell
8,297
-48
-0.6% -$4.03K 0.02% 535
2023
Q4 		$664K Buy
8,345
+1,225
+17% +$81.9K 0.03% 463
2023
Q3 		$498K Buy
+7,120
New +$532K 0.02% 527

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wedbush Securities's AXSM Position: Q3 2024 in Review

Wedbush Securities sold out of Axsome Therapeutics (AXSM) in Q3 2024, closing a stake of 4,818 shares — an estimated $388K sold.

Wedbush Securities first reported a position in AXSM in Q3 2023 and held it in 4 quarters. The position peaked at $664K in Q4 2023. 278 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • Wedbush Securities reported no remaining Axsome Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Wedbush Securities sold 4,818 Axsome Therapeutics shares in Q3 2024, an estimated $388K.
  • Wedbush Securities first reported a position in Axsome Therapeutics in Q3 2023 and held it in 4 quarters.
  • Wedbush Securities's Axsome Therapeutics position peaked at $664K in Q4 2023.
  • 278 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Wedbush Securities's 13F filing for Q3 2024, filed 8 Nov 2024.